Terms: = Ovarian cancer AND PAX8, ENSG00000125618, 7849 AND Treatment
27 results:
1. ovarian Mesonephric-Like Adenocarcinoma With Recurrent Liver Metastases: A Case Report with Analysis of Therapeutic Molecular Targets.
Sugitani A; Ogawa A; Yoshida H; Kobayashi-Kato M; Kikkawa N; Tanase Y; Uno M; Ishikawa M; Kato T
Int J Surg Pathol; 2024 May; 32(3):578-585. PubMed ID: 37345348
[TBL] [Abstract] [Full Text] [Related]
2.
Bulutay P; Vatansever D; Taskiran C; Mericoz CA; Tokat F; Kapucuoglu N; Kulac I
Indian J Pathol Microbiol; 2023; 66(2):392-395. PubMed ID: 37077094
[TBL] [Abstract] [Full Text] [Related]
3. Amplified therapeutic targets in high-grade serous ovarian carcinoma - a review of the literature with quantitative appraisal.
Talbot T; Lu H; Aboagye EO
Cancer Gene Ther; 2023 Jul; 30(7):955-963. PubMed ID: 36804485
[TBL] [Abstract] [Full Text] [Related]
4. Carcinoid ovary with synchronous carcinoid tumour of the appendix: report of a rare occurrence with review of literature.
Baruah U; Tak A; Kakoti L; Barmon D
BMJ Case Rep; 2022 Jun; 15(6):. PubMed ID: 35750423
[TBL] [Abstract] [Full Text] [Related]
5. SOX17 and pax8 constitute an actionable lineage-survival transcriptional complex in ovarian cancer.
Lin L; Shi K; Zhou S; Cai MC; Zhang C; Sun Y; Zang J; Cheng L; Ye K; Ma P; Shen P; Zhang M; Cheng Y; Qi C; Li Y; Yin X; Zheng Y; Tan L; Zhuang G; Zang R
Oncogene; 2022 Mar; 41(12):1767-1779. PubMed ID: 35124696
[TBL] [Abstract] [Full Text] [Related]
6. Targeting the DIO3 enzyme using first-in-class inhibitors effectively suppresses tumor growth: a new paradigm in ovarian cancer treatment.
Moskovich D; Finkelshtein Y; Alfandari A; Rosemarin A; Lifschytz T; Weisz A; Mondal S; Ungati H; Katzav A; Kidron D; Mugesh G; Ellis M; Lerer B; Ashur-Fabian O
Oncogene; 2021 Nov; 40(44):6248-6257. PubMed ID: 34556811
[TBL] [Abstract] [Full Text] [Related]
7. pax8, an Emerging Player in ovarian cancer.
Gokulnath P; Soriano AA; de Cristofaro T; Di Palma T; Zannini M
Adv Exp Med Biol; 2021; 1330():95-112. PubMed ID: 34339032
[TBL] [Abstract] [Full Text] [Related]
8. Molecular Characterization of Muellerian Tumors of the Urinary Tract.
Ortiz-Brüchle N; Wucherpfennig S; Rose M; Garczyk S; Bertz S; Hartmann A; Reis H; Szarvas T; Kiss A; Bremmer F; Golz R; Knüchel R; Gaisa NT
Genes (Basel); 2021 Jun; 12(6):. PubMed ID: 34200508
[TBL] [Abstract] [Full Text] [Related]
9. Global miRNA/proteomic analyses identify miRNAs at 14q32 and 3p21, which contribute to features of chronic iron-exposed fallopian tube epithelial cells.
Chhabra R; Rockfield S; Guergues J; Nadeau OW; Hill R; Stevens SM; Nanjundan M
Sci Rep; 2021 Mar; 11(1):6270. PubMed ID: 33737539
[TBL] [Abstract] [Full Text] [Related]
10. Primary ovarian angiosarcoma: a rare and recognizable ovarian tumor.
Ye H; Lin M; Li R; Qin S; Hou G; Chen H; Li X
J Ovarian Res; 2021 Jan; 14(1):21. PubMed ID: 33509230
[TBL] [Abstract] [Full Text] [Related]
11. Extra-abdominal ovarian cancer presenting with breast metastases at diagnosis: Case report and literature review.
Ferrari F; Ficarelli S; Forte S; Valenti G; Ardighieri L; Sartori E; Odicino F
Eur J Obstet Gynecol Reprod Biol; 2020 Dec; 255():211-221. PubMed ID: 33152565
[TBL] [Abstract] [Full Text] [Related]
12. Establishment and characterization of a cell line and patient-derived xenograft (PDX) from peritoneal metastasis of low-grade serous ovarian carcinoma.
De Thaye E; Van de Vijver K; Van der Meulen J; Taminau J; Wagemans G; Denys H; Van Dorpe J; Berx G; Ceelen W; Van Bocxlaer J; De Wever O
Sci Rep; 2020 Apr; 10(1):6688. PubMed ID: 32317693
[TBL] [Abstract] [Full Text] [Related]
13. Somatically Derived Yolk Sac Tumor of the Ovary in a Young Woman.
Hodgson A; Ghorab Z; Parra-Herran C
Int J Gynecol Pathol; 2021 May; 40(3):296-300. PubMed ID: 32209818
[TBL] [Abstract] [Full Text] [Related]
14. [Un- and dedifferentiated endometrial carcinoma : A rare entity with a wide range of differential diagnosis].
Höhn AK; Brambs CE; Opitz S; Erber R; Hartmann A; Horn LC
Pathologe; 2019 Nov; 40(6):609-618. PubMed ID: 31578630
[TBL] [Abstract] [Full Text] [Related]
15. Clear cell carcinoma of testis: A review.
Lin M; Awalt H; Ayala AG; Ro JY
Ann Diagn Pathol; 2019 Jun; 40():26-29. PubMed ID: 30921621
[TBL] [Abstract] [Full Text] [Related]
16. Breast metastasis two years after pelvic surgery and adjuvant chemotherapy for serous ovarian cancer.
Della Corte L; Giampaolino P; Fabozzi A; Cieri M; Zizolfi B; Morra I; Bifulco G
Gynecol Endocrinol; 2019 Mar; 35(3):211-213. PubMed ID: 30449229
[TBL] [Abstract] [Full Text] [Related]
17. Comparative clinicopathological and cytomorphological analyses of peritoneal carcinomatosis associated with metastatic breast carcinoma and primary peritoneal/ovarian carcinoma in patients with a history of breast carcinoma.
Na K; Lee JY; Sung JY; Kim GM; Koo JS; Kim HS
Virchows Arch; 2018 Aug; 473(2):165-175. PubMed ID: 29926183
[TBL] [Abstract] [Full Text] [Related]
18. PTEN loss in the fallopian tube induces hyperplasia and ovarian tumor formation.
Russo A; Czarnecki AA; Dean M; Modi DA; Lantvit DD; Hardy L; Baligod S; Davis DA; Wei JJ; Burdette JE
Oncogene; 2018 Apr; 37(15):1976-1990. PubMed ID: 29367766
[TBL] [Abstract] [Full Text] [Related]
19. Chemosensitivity of BRCA1-Mutated ovarian cancer Cells and Established Cytotoxic Agents.
van Haaften C; van Eendenburg J; Boot A; Corver WE; Haans L; van Wezel T; Trimbos JB
Int J Gynecol Cancer; 2017 Oct; 27(8):1571-1578. PubMed ID: 28604461
[TBL] [Abstract] [Full Text] [Related]
20. Expression of WT1 and pax8 in the epithelial tumours of Malaysian women with ovarian cancer.
Rhodes A; Vallikkannu N; Jayalakshmi P
Br J Biomed Sci; 2017 Apr; 74(2):65-70. PubMed ID: 28367736
[TBL] [Abstract] [Full Text] [Related]
[Next]
